Clinical characteristics of functional outcome groups
| mRS 0–2 (119) | mRS 3–6 (88) | p Value | |
|---|---|---|---|
| Age (year) | 67.16±9.86 | 71.67±10.07 | 0.01 |
| Gender, male (n, %) | 78, 65.5 | 49, 55.7 | 0.085 |
| HT (n, %) | 93, 78.2 | 68, 77.3 | 0.881 |
| DM (n, %) | 49, 41.2 | 47, 53.4 | 0.081 |
| Chronic heart disease (n, %) | 18, 15.1 | 7, 8.0 | 0.118 |
| LDL-C (mmol/L) | 2.94±1.11 | 3.34±1.10 | 0.014 |
| HDL-C (mmol/L) | 1.25 (0.70–2.40) | 1.24±0.33 | 0.294 |
| Triglycerides (mmol/L) | 1.50 (0.40–5.40) | 1.40 (0.60–11.70) | 0.306 |
| Total cholesterol (mmol/L) | 4.94±1.28 | 5.24±1.16 | 0.09 |
| Previous TIA (n, %) | 19, 16 | 3, 3.4 | 0.004 |
| Previous ischaemic stroke (n, %) | 25, 21 | 28, 31.8 | 0.078 |
| Smoking (n, %) | 36, 30.3 | 23, 26.1 | 0.517 |
| Alcoholism (n, %) | 15, 12.6 | 9, 10.2 | 0.597 |
| Stroke onset to recruitment (day) | 6 (0–95) | 5 (0–21) | 0.010 |
| NIHSS at recruitment | 4 (0–22) | 9 (3–20) | <0.001 |
| Admission systolic BP (mm Hg) | 164.90±31.62 | 159.16±19.22 | 0.122 |
| Admission diastolic BP (mm Hg) | 86.00 (52–134) | 82.95±12.40 | 0.345 |
| ECP duration (h) | 35 (11–35) | 23 (10–35) | <0.001 |
| Aspirin (n, %) | 106, 89.1 | 84, 95.5 | 0.098 |
| Clopidogrel (n, %) | 11, 9.2 | 5, 5.7 | 0.343 |
| ACEI (n, %) | 56, 47.1 | 51, 58 | 0.121 |
| β Blocker (n, %) | 13, 10.9 | 16, 18.2 | 0.137 |
| Calcium channel blocker (n, %) | 28, 23.5 | 23, 26.1 | 0.330 |
| Statin (n, %) | 90, 75.6 | 73, 83.0 | 0.203 |
The numbers in italics are those p value <0.05 in order to address the statistic significance.
BP, blood pressure; DM, diabetes mellitus; ECP, external counterpulsation; HDL-C, high-density lipoprotein cholesterol; HT, hypertension; LDL-C, low-density lipoprotein cholesterol; mRS, modified-Rankin scores; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack. Continuous data were presented as the mean and SD if normally distributed or as the median and range if skew distributed.